NASDAQ:VIRI Virios Therapeutics (VIRI) Stock Price, News & Analysis → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free VIRI Stock Alerts $0.41 -0.01 (-2.37%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.41▼$0.4350-Day Range$0.31▼$0.5852-Week Range$0.28▼$2.42Volume67,436 shsAverage Volume122,237 shsMarket Capitalization$7.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Virios Therapeutics alerts: Email Address Ad Awesomely, LLCAutomatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free. About Virios Therapeutics Stock (NASDAQ:VIRI)Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.Read More VIRI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIRI Stock News HeadlinesMay 2, 2024 | globenewswire.comVirios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024April 14, 2024 | finance.yahoo.comVirios Therapeutics, Inc. (VIRI)May 4, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.March 28, 2024 | investing.comVirios Therapeutics seeks global patent for antiviral comboMarch 26, 2024 | globenewswire.comVirios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDFebruary 29, 2024 | investing.comVirios Therapeutics announces salary cuts for employees and boardFebruary 29, 2024 | markets.businessinsider.comVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 29, 2024 | globenewswire.comVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsMay 4, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.February 28, 2024 | markets.businessinsider.comVirios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesFebruary 28, 2024 | globenewswire.comVirios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesFebruary 27, 2024 | investing.comVirios Therapeutics Llc (VIRI)February 25, 2024 | msn.comVirios Therapeutics (VIRI) Price Target Increased by 14.29% to 4.08February 9, 2024 | morningstar.comVirios Therapeutics Inc Ordinary Shares VIRIFebruary 7, 2024 | finance.yahoo.comVIRI: Moving IMC-2 into Phase 2 Program in Long COVIDFebruary 6, 2024 | finance.yahoo.comFibromyalgia Treatment Market revenue to cross USD 536 Million by 2033, says Research NesterJanuary 23, 2024 | benzinga.comVirios Therapeutics Stock (NASDAQ:VIRI) Dividends: History, Yield and DatesJanuary 22, 2024 | finanznachrichten.deVirios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDJanuary 22, 2024 | finance.yahoo.comVirios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDJanuary 2, 2024 | markets.businessinsider.comVirios Therapeutics Reports Receipt Of FDA's Feedback On Requirements For Advancing IMC-2January 2, 2024 | finance.yahoo.comVirios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVIDDecember 7, 2023 | morningstar.comVirios Therapeutics Inc Ordinary SharesNovember 14, 2023 | finance.yahoo.comVirios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | finance.yahoo.comVIRI: Provides Overview of Phase 3 Program in FibromyalgiaNovember 13, 2023 | msn.comVirios Therapeutics GAAP EPS of -$0.06 beats by $0.04November 13, 2023 | finance.yahoo.comVirios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 13, 2023 | finance.yahoo.comVirios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive VIRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/04/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VIRI CUSIPN/A CIK1818844 Webwww.virios.com Phone866-620-8655FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-110.15% Return on Assets-100.18% Debt Debt-to-Equity RatioN/A Current Ratio11.60 Quick Ratio11.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book2.06Miscellaneous Outstanding Shares19,260,000Free Float17,005,000Market Cap$7.93 million OptionableOptionable Beta1.87 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Gregory Duncan (Age 58)Chairman & CEO Comp: $559.59kDr. William L. Pridgen M.D. (Age 63)Founder & Director Comp: $35kMs. Angela Walsh (Age 57)CFO, SVP of Finance, Corporate Secretary & Treasurer Comp: $281.28kDr. R. Michael Gendreau M.D. (Age 68)Ph.D., Chief Medical Officer Comp: $420.64kMr. Ralph D. Grosswald M.P.H. (Age 55)Senior Vice President of Operations Comp: $274.69kMs. Carol Duffy Ph.D.Chief Scientific AdvisorMore ExecutivesKey CompetitorsUniverse PharmaceuticalsNYSE:UPCGraybug VisionNASDAQ:GRAYeFFECTOR TherapeuticsNASDAQ:EFTRNuCanaNASDAQ:NCNAAddex TherapeuticsNASDAQ:ADXNView All CompetitorsInsidersWilliam PridgenBought 15,335 shares on 8/21/2023Total: $19,935.50 ($1.30/share)Gregory Scott DuncanBought 25,000 shares on 8/17/2023Total: $31,250.00 ($1.25/share)View All Insider Transactions VIRI Stock Analysis - Frequently Asked Questions How have VIRI shares performed in 2024? Virios Therapeutics' stock was trading at $0.5750 at the beginning of the year. Since then, VIRI shares have decreased by 28.4% and is now trading at $0.4115. View the best growth stocks for 2024 here. Are investors shorting Virios Therapeutics? Virios Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 217,500 shares, an increase of 27.8% from the March 15th total of 170,200 shares. Based on an average trading volume of 386,400 shares, the days-to-cover ratio is presently 0.6 days. View Virios Therapeutics' Short Interest. When is Virios Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VIRI earnings forecast. How can I listen to Virios Therapeutics' earnings call? Virios Therapeutics will be holding an earnings conference call on Thursday, May 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Virios Therapeutics' earnings last quarter? Virios Therapeutics, Inc. (NASDAQ:VIRI) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.03. When did Virios Therapeutics IPO? Virios Therapeutics (VIRI) raised $30 million in an initial public offering (IPO) on Thursday, December 17th 2020. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. How do I buy shares of Virios Therapeutics? Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIRI) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCFW: 234x GainWeiss RatingsCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
